生命科学资讯

Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market

Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push

Hims reports 2025 earnings, shares details on GLP-1 pill decisions

Astellas pays $240M cash for Vir's prostate cancer drug

QurAlis' ALS drug sees early positive signal, but questions remain

Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act

Fortress to sell priority review voucher for $205M

FDA unveils long-awaited guidance on new pathway for individualized therapies

Flagship's Generate targets $2B+ valuation with Nasdaq IPO

AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago

Frontier, Harbour do licensing deals with GSK, Solstice

A federal experiment opens up a new market for digital health — if it works

Roche to stop work on bone health treatment for Duchenne

Roche to stop work on bone health treatment for Duchenne - Endpoints News

Merck reorganizes; Blackstone to fund trials for J&J drug

First test of gene therapy for rare form of autism is underway

Gilead to acquire cell therapy partner Arcellx for $7.8B

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

MoonLake has 'confidence' ahead of FDA submission, discloses mid-stage arthritis win

Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more